Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 4, 2026, 4:15 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 697–720 of 5,055 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Capsule 2 Clear all

Conditions: Healthy
Interventions: MK-2828, Itraconazole, Midazolam; Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 24 Years to 60 Years
Enrollment: 29 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Chronic Obstructive Pulmonary Disease
Interventions: Indacaterol 150 μg, Tiotropium 18 μg, Placebo to indacaterol, Placebo to tiotropium; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 40 Years and older
Enrollment: 1,598 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 25
States / cities: Birmingham, Alabama • Jasper, Alabama • Phoenix, Arizona + 22 more

Conditions: Peripheral Vascular Disease, Intermittent Claudication, Peripheral Arterial Disease
Interventions: Levocarnitine tartrate, cilostazol; Dietary Supplement · Drug
Lead sponsor: Colorado Prevention Center; Other
Eligibility: 40 Years and older
Enrollment: 164 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2010
U.S. locations: 24
States / cities: Phoenix, Arizona • Little Rock, Arkansas • Palo Alto, California + 18 more

Conditions: Colorectal Lesions
Interventions: PillCam Colon 2, Colonoscopy; Device
Lead sponsor: Medtronic - MITG; Industry
Eligibility: 50 Years to 75 Years
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2011
U.S. locations: 1
States / cities: Chesapeake, Virginia

Conditions: Sudden Sensorineural Hearing Loss
Interventions: Statin, methylprednisolone, dexamethasone, Placebo; Drug
Lead sponsor: Northwestern University; Other
Eligibility: 18 Years to 80 Years
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Reproductive Issues
Interventions: Vitamin D, Placebo; Dietary Supplement · Other
Lead sponsor: National Institute of Environmental Health Sciences (NIEHS); NIH
Eligibility: 19 Years to 40 Years · Female only
Enrollment: 998 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 2
States / cities: Detroit, Michigan • Research Triangle Park, North Carolina

Conditions: Aging
Interventions: Rapamycin, Everolimus, Placebo; Drug · Other
Lead sponsor: The University of Texas Health Science Center at San Antonio; Other
Eligibility: 65 Years to 90 Years
Enrollment: 194 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Constipation
Interventions: Vibrating capsule; Device
Lead sponsor: Vibrant Ltd.; Industry
Eligibility: 22 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: High Triglyceride Level, HIV Infection
Interventions: Lovaza; Drug
Lead sponsor: Tufts University; Other
Eligibility: 18 Years and older
Enrollment: 129 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2015
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Type 2 Diabetes Mellitus
Interventions: XW014, Placebo; Drug
Lead sponsor: Sciwind Biosciences USA Co., Ltd.; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 127 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2024
U.S. locations: 3
States / cities: Lenexa, Kansas • San Antonio, Texas • Salt Lake City, Utah

Conditions: Osteosarcoma
Interventions: Lenvatinib, Ifosfamide, Etoposide; Drug
Lead sponsor: Eisai Inc.; Industry
Eligibility: 2 Years to 25 Years
Enrollment: 81 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 16
States / cities: Birmingham, Alabama • Loma Linda, California • Orange, California + 13 more

Conditions: Chronic Lymphocytic Leukemia
Interventions: Pembrolizumab, Ibrutinib; Drug
Lead sponsor: H. Lee Moffitt Cancer Center and Research Institute; Other
Eligibility: 18 Years and older
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2023
U.S. locations: 1
States / cities: Tampa, Florida

Conditions: Dietary Supplements
Interventions: Muscadine grape seed supplement; Dietary Supplement
Lead sponsor: Wake Forest University Health Sciences; Other
Eligibility: 18 Years to 65 Years
Enrollment: 50 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2008
U.S. locations: 1
States / cities: Winston-Salem, North Carolina

Conditions: Drug Resistant Partial Onset Seizure
Interventions: ganaxolone, Placebo; Drug
Lead sponsor: Marinus Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 405 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2016
U.S. locations: 33
States / cities: Birmingham, Alabama • Phoenix, Arizona • Sun City, Arizona + 25 more

Conditions: Asthma
Interventions: MRx-4DP0004, Placebo; Drug
Lead sponsor: 4D pharma plc; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 34 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2023
U.S. locations: 1
States / cities: Portland, Oregon

Conditions: Healthy Volunteer
Interventions: Icalcaprant; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 16 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: Anaheim, California

Conditions: Liver Cirrhosis, Sarcopenia
Interventions: LPCN 1148, Placebo; Drug
Lead sponsor: Lipocine Inc.; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 10
States / cities: Scottsdale, Arizona • Los Angeles, California • San Francisco, California + 6 more

Conditions: AXIN1 Gene Mutation, APC Gene Mutation, Solid Tumor
Interventions: REC-4881; Drug
Lead sponsor: Recursion Pharmaceuticals Inc.; Industry
Eligibility: 55 Years and older
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 13
States / cities: San Diego, California • Santa Barbara, California • Denver, Colorado + 10 more

Conditions: Hypercortisolism
Interventions: Relacorilant, Placebo; Drug · Other
Lead sponsor: Corcept Therapeutics; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 137 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2024
U.S. locations: 22
States / cities: Birmingham, Alabama • Stanford, California • Torrance, California + 19 more

Conditions: Solid Tumors
Interventions: MSX-122; Drug
Lead sponsor: Metastatix, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 27 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Obesity and Cardiovascular Risk
Interventions: Oral BGE-102, Oral Placebo Matching BGE-102; Drug
Lead sponsor: BioAge Labs, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 160 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026
U.S. locations: 16
States / cities: Chandler, Arizona • Peoria, Arizona • Tucson, Arizona + 13 more

Conditions: Kidney Transplant
Interventions: ramipril; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 229 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2013
U.S. locations: 24
States / cities: Los Angeles, California • San Francisco, California • Aurora, Colorado + 16 more

Conditions: Posttraumatic Stress Disorder With Attention Defic
Interventions: Atomoxetine, Placebo; Drug
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: 18 Years to 75 Years
Enrollment: 160 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: Charleston, South Carolina

Conditions: Intestinal Disorders, Bowel Diseases, Inflammatory
Interventions: TD-1473 oral capsule, [14C]-TD-1473 IV bolus, [14C]-TD-1473 Oral Capsule; Drug
Lead sponsor: Theravance Biopharma; Industry
Eligibility: 19 Years to 55 Years · Male only
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018
U.S. locations: 1
States / cities: Lincoln, Nebraska

Search by objective public record fields.

A Clinical Trial in Healthy Participants to Learn How Itraconazole Affects MK-2828 Levels and How MK-2828 Affects Midazolam Levels (MK-2828-007)

A Study to Compare the Lung Effect of Indacaterol and Tiotropium in Chronic Obstructive Pulmonary Disease (COPD)

Evaluation of Cilostazol in Combination With L-Carnitine

Evaluation of Capsule Endoscopy With PillCam® Colon 2 in Visualization of the Colon

Oral Statins and Protection From Hearing Loss

The Investigation of Vitamin D and Menstrual Cycles Trial, the inVitD Trial: A Phase II Clinical Trial

RESTOR: PK/PD mTORi Inhibition in Older Adults

Ease of Use, Tolerability, Efficacy and Safety of the Vibrant Capsule Administered in the Home Environment

The Impact of Omega Three Fatty Acids on Vascular Function in HIV

XW014 in Healthy Subjects and Patients With Type 2 Diabetes Mellitus (T2DM)

A Study to Compare the Efficacy and Safety of Ifosfamide and Etoposide With or Without Lenvatinib in Children, Adolescents and Young Adults With Relapsed and Refractory Osteosarcoma

Ibrutinib and PD-1 Blockade in High Risk Lymphocytic Leukemia

Muscadine Grape Seed Supplementation and Vascular Function

Phase 3 Study of Adjunctive Ganaxolone in Adults With Drug-resistant Partial Onset Seizures and Open-label Extension

A Study of MRx-4DP0004 in Asthma

A Single Dose Study to Assess Adverse Events and How Oral Icalcaprant Moves Through the Body in Healthy Adult Japanese and Han Chinese Participants

A Study to Assess the Efficacy, Safety, and Tolerability of Oral LPCN 1148 in Male Subjects With Cirrhosis of the Liver and Sarcopenia

A Study of REC-4881 in Participants With Cancers Which Have an AXIN1 or APC Mutation

A Study of the Efficacy and Safety of Relacorilant in Patients With Cortisol-Secreting Adrenal Adenomas

MSX-122 Administered Orally in Patients With Refractory Metastatic or Locally Advanced Solid Tumors

A Phase 2 Study to Evaluate the Pharmacodynamics, Safety and Tolerability of BGE-102 in Participants With Obesity and Cardiovascular Risk Factors

Study Evaluating The Effect Of Ramipril On Urinary Protein Excretion In Renal Transplant Patients Converted To Sirolimus

Atomoxetine and Executive Function in PTSD

TD-1473 Absorption, Distribution, Metabolism and Excretion (ADME) Study in Healthy Male Subjects